Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

KB-2115 begins phase II for dyslipidemia

Nov. 7, 2006

Inyx to manufacture Plethora's topical HFA aerosol for premature ejaculation

Nov. 7, 2006

Lack of toxic effects of Phytosoya isoflavone extract on the endometrium in postmenopausal women

Nov. 6, 2006

Phytoestrogen ERr 731 shows efficacy in controlled clinical trial

Nov. 6, 2006

NDA filed for Somatuline Autogel

Nov. 6, 2006

AKP-101 manufactured for type 2 diabetes trials

Nov. 3, 2006

Emisphere's oral insulin shows efficacy in type 2 diabetes patients

Nov. 2, 2006

Tesofensine cleared for phase I/II metabolic study

Nov. 2, 2006

MB-07811 studied in phase I for management of hyperlipidemia

Nov. 2, 2006

Preclinical studies of FTI tipifarnib encourage clinical investigation in HGPS

Oct. 31, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...